Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Diagnosis-Specific Graded Prognostic Assessment (DS-GPA)

The DS-GPA refines brain metastases prognosis by using tumour-specific prognostic factors that vary by primary cancer type, validated in 3,940 patients across multiple RTOG trials.

Evidence-based context for fast calculator use

Purpose:
Provide tumour-specific survival estimates for brain metastases patients
Population:
Brain metastases patients stratified by primary cancer (NSCLC, breast, melanoma, renal, GI)
Factors:
Varies by primary: KPS, Age, Number of brain mets, Extracranial mets, Tumour subtype
Reference:
Sperduto et al., JCO 2012
HomeDiagnosis-Specific GPA (Brain Mets)
Pin your most used calculators here by clicking the star in the dropdown.

Diagnosis-Specific GPA (Brain Mets)

Clinical Context & Background

The Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) is the modern standard for brain metastasis prognosis. This tool uses the updated Lung-molGPA (2017), Melanoma-molGPA (2017), Breast GPA (2020 Update), and Renal/GI GPA models.
Primary Source EvidenceSperduto PW, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827–831. (See also JCO 2012, 2020).
Formula Logic
Sum of points varies by Primary Site.

Reference Data

GPA ScoreMedian Survival (Months)
0 - 1.0Poor (~ 3-6 mo)
1.5 - 2.0Intermediate (~ 9-13 mo)
2.5 - 3.0Good (~ 15-25 mo)
3.5 - 4.0Excellent (> 30 mo)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Diagnosis-Specific GPA (Brain Mets) when diagnosis-Specific GPA estimates survival in brain metastases from Lung, Breast, Melanoma, Renal, or GI primaries to guide radiation treatment planning.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 1.0 through 3.5 - 4.0.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary histology, molecular classification, number and location of lesions, extracranial disease, performance status, and treatment era.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Generic brain-metastasis and disease-specific GPA models should not be interchanged.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with primary or metastatic central nervous system disease in the setting described by the model

How to apply this result

For a representative case, verify Primary Site, Karnofsky Performance Status, Age, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Neuro-Oncology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

WHO CNS Tumor Grade (2021)RPA (Brain Metastases)GPA (Graded Prognostic Assessment)

Frequently Asked Questions

When should Diagnosis-Specific GPA (Brain Mets) be used?

Use it for patients with primary or metastatic central nervous system disease in the setting described by the model when all required inputs and the intended clinical setting are confirmed.

Can Diagnosis-Specific GPA (Brain Mets) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.